Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
John A. McCulloch, Diwakar Davar, Richard R. Rodrigues, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 545-556
Open Access | Times Cited: 286

Showing 1-25 of 286 citing articles:

Hallmarks of aging: An expanding universe
Carlos López-Otı́n, Marı́a A. Blasco, Linda Partridge, et al.
Cell (2023) Vol. 186, Iss. 2, pp. 243-278
Open Access | Times Cited: 2710
Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment
Mackenzie Bender, Alex McPherson, Catherine M. Phelps, et al.
Cell (2023) Vol. 186, Iss. 9, pp. 1846-1862.e26
Open Access | Times Cited: 299
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
Yuting Lu, Xiangliang Yuan, Miao Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 271
T cells specific for α-myosin drive immunotherapy-related myocarditis
Margaret L. Axelrod, Wouter C. Meijers, Elles M. Screever, et al.
Nature (2022) Vol. 611, Iss. 7937, pp. 818-826
Open Access | Times Cited: 203
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Bertrand Routy, John Lenehan, Wilson H. Miller, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 2121-2132
Closed Access | Times Cited: 201
The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer
Gauri Mirji, Alison Worth, Sajad A. Bhat, et al.
Science Immunology (2022) Vol. 7, Iss. 75
Open Access | Times Cited: 161
Targeting the gut microbiota for cancer therapy
Miriam R. Fernandes, Poonam Aggarwal, Raquel Costa, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 12, pp. 703-722
Closed Access | Times Cited: 149
Embracing cancer complexity: Hallmarks of systemic disease
Charles Swanton, Elsa Bernard, Chris Abbosh, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1589-1616
Open Access | Times Cited: 146
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
Rebecca Simpson, Erin R. Shanahan, Marcel Batten, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2344-2352
Closed Access | Times Cited: 141
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Christoph K. Stein‐Thoeringer, Neeraj Saini, Eli Zamir, et al.
Nature Medicine (2023) Vol. 29, Iss. 4, pp. 906-916
Open Access | Times Cited: 114
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications
Jie Fang, Chen-Huan Yu, Xuejian Li, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 101
Biomarkers for immunotherapy of hepatocellular carcinoma
Tim F. Greten, Augusto Villanueva, Firouzeh Korangy, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 780-798
Closed Access | Times Cited: 94
Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction
József Tı́már, Andrea Ladányi
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5384-5384
Open Access | Times Cited: 83
Gut microbiota and hypertension: association, mechanisms and treatment
Zhihua Yang, Qingchun Wang, Yangxi Liu, et al.
Clinical and Experimental Hypertension (2023) Vol. 45, Iss. 1
Open Access | Times Cited: 79
Drug-microbiota interactions: an emerging priority for precision medicine
Qing Zhao, Yao Chen, Weihua Huang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 79
Machine learning for microbiologists
Francesco Asnicar, Andrew Maltez Thomas, Andrea Passerini, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 4, pp. 191-205
Open Access | Times Cited: 79
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Andrew Maltez Thomas, Marine Fidelle, Bertrand Routy, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 9, pp. 583-603
Closed Access | Times Cited: 69
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
Su Yin Lim, Elena Shklovskaya, Jenny Lee, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 59
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Ashley M. Holder, Aikaterini Dedeilia, Kailan Sierra-Davidson, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 7, pp. 498-512
Closed Access | Times Cited: 54
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Rebecca Simpson, Erin R. Shanahan, Richard A. Scolyer, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 697-715
Closed Access | Times Cited: 53
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Johannes R. Björk, Laura A. Bolte, Andrew Maltez Thomas, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 785-796
Open Access | Times Cited: 48
Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome
Lisa Derosa, Valerio Iebba, Carolina Alves Costa Silva, et al.
Cell (2024) Vol. 187, Iss. 13, pp. 3373-3389.e16
Open Access | Times Cited: 43
Vitamin D regulates microbiome-dependent cancer immunity
Evangelos Giampazolias, Mariana Pereira da Costa, Khiem C. Lam, et al.
Science (2024) Vol. 384, Iss. 6694, pp. 428-437
Open Access | Times Cited: 42
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Íñigo Les, Mireia Martínez, Inés Pérez-Francisco, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1629-1629
Open Access | Times Cited: 41
Role of the microbiota in response to and recovery from cancer therapy
Stephen J. Blake, Yochai Wolf, Ben Boursi, et al.
Nature reviews. Immunology (2023) Vol. 24, Iss. 5, pp. 308-325
Closed Access | Times Cited: 41
Page 1 - Next Page

Scroll to top